具核梭菌与鲍曼不动杆菌在胃癌中的协同致癌效应

Synergistic carcinogenic effects of Fusobacterium nucleatum and Acinetobacter baumannii in gastric cancer

摘要

近年来，研究表明具核梭菌和鲍曼不动杆菌可能在胃癌的发生和进展中发挥着重要的协同致癌作用。具核梭菌通过脂多糖及代谢产物激活促炎信号通路，引发慢性炎症反应，促进癌细胞的增殖及免疫逃逸。鲍曼不动杆菌通过生物膜形成、慢性炎症反应、免疫逃逸以及多重耐药性等机制加剧胃部微生态失衡，进一步促进胃癌的进展。本文系统探讨了这两种细菌在胃癌中的协同致癌机制，分析了它们如何通过微生态失衡、免疫逃逸和肿瘤微环境的重塑等途径影响胃癌的发生和进展，并提出它们作为胃癌潜在生物标志物和靶向治疗的新方向。未来的研究应聚焦于具核梭菌和鲍曼不动杆菌的协同致癌机制及其在个体化治疗中的应用，探索二者在胃癌的早期诊断和预后评估中的实际价值。

Abstract

In recent years, studies have shown thatFusobacterium nucleatum andAcinetobacter baumannii might play a significant synergistic carcinogenic role in the occurrence and progression of gastric cancer.Fusobacterium nucleatum activates pro-inflammatory signaling pathways through lipopolysaccharides and metabolites, triggering chronic inflammation, promoting cancer cell proliferation, and facilitating immune evasion.Acinetobacter baumannii exacerbates the imbalance of the gastric microbiome through mechanisms such as biofilm formation, chronic inflammatory responses, immune evasion, and multidrug resistance, further promoting the progression of gastric cancer. This article systematically explores the synergistic carcinogenic mechanisms of these two bacteria in gastric cancer, and analyzes how they influence the occurrence and progression of gastric cancer through pathways such as microbial dysbiosis, immune evasion, and remodeling of the tumor microenvironment. It also proposes their potential as biomarkers and novel targets for targeted therapy in gastric cancer. Future research should focus on the synergistic carcinogenic mechanisms ofFusobacterium nucleatum andAcinetobacter baumannii and their application in personalized therapy, exploring their practical value in the early diagnosis and prognosis evaluation of gastric cancer.

关键词

具核梭菌 / 鲍曼不动杆菌 / 胃癌 / 致癌机制 / 协同作用

Key words

Fusobacterium nucleatum / Acinetobacter baumannii / Gastric cancer / Carcinogenic mechanisms / Synergistic effects

参考文献

[1] BESSÈDE E, MÉGRAUD F. Microbiota and gastric cancer[J]. Semin Cancer Biol, 2022, 86(Pt 3): 11-17.

[2] PETKEVICIUS V, LEHR K, KUPCINSKAS J, et al. Fusobacterium nucleatum: Unraveling its potential role in gastric carcinogenesis[J]. World J Gastroenterol, 2024, 30(35): 3972-3984.

[3] LEHR K, NIKITINA D, VILCHEZ-VARGAS R, et al. Microbial composition of tumorous and adjacent gastric tissue is associated with prognosis of gastric cancer[J]. Sci Rep, 2023, 13(1): 4640.

[4] ȘURLIN P, NICOLAE F M, ȘURLIN V M, et al. Could periodontal disease through periopathogen Fusobacterium nucleatum be an aggravating factor for gastric cancer?[J]. J Clin Med, 2020, 9(12): 3885.

[5] WHITEWAY C, BREINE A, PHILIPPE C, et al. Acinetobacter baumannii[J]. Trends Microbiol, 2022, 30(2): 199-200.

[6] 李招吟倩, 谢静玲, 杨葵, 等 . 鲍曼不动杆菌感染及治疗的研究进展[J]. 中国抗生素杂志, 2022, 47(8): 766-771.

[7] WANG N, FANG J Y . Fusobacterium nucleatum, a key pathogenic factor and microbial biomarker for colorectal cancer[J]. Trends Microbiol, 2023, 31(2): 159-172.

[8] GALASSO L, TERMITE F, MIGNINI I, et al. Unraveling the role of Fusobacterium nucleatum in colorectal cancer: Molecular mechanisms and pathogenic insights[J]. Cancers (Basel), 2025, 17(3): 368.

[9] ENGEVIK M A, DANHOF H A, RUAN W, et al. Fusobacterium nucleatum secretes outer membrane vesicles and promotes intestinal inflammation[J]. mBio, 2021, 12(2): e02706-20.

[10] ALON-MAIMON T, MANDELBOIM O, BACHRACH G. Fusobacterium nucleatum and cancer[J]. Periodontol, 2022, 89(1): 166-180.

[11] HU L, LIU Y, KONG X, et al. Fusobacterium nucleatum facilitates M2 macrophage polarization and colorectal carcinoma progression by activating TLR4/NF-κB/S100A9 cascade[J]. Front Immunol, 2021, 12: 658681.

[12] MCILVANNA E, LINDEN G J, CRAIG S G, et al. Fusobacterium nucleatum and oral cancer: A critical review[J]. BMC Cancer, 2021, 2(1): 1212.

[13] CHEN T, LI Q, WU J, et al. Fusobacterium nucleatum promotes M2 polarization of macrophages in the microenvironment of colorectal tumours via a TLR4-dependent mechanism[J]. Cancer Immunol Immunother, 2018, 67(10): 1635-1646.

[14] WU Q L, FANG X T, WAN X X, et al. Fusobacterium nucleatum-induced imbalance in microbiome-derived butyric acid levels promotes the occurrence and development of colorectal cancer[J]. World J Gastroenterol, 2024, 30(14): 2018-2037.

[15] QU R, ZHANG Y, MA Y, et al. Role of the gut microbiota and its metabolites in tumorigenesis or development of colorectal cancer[J]. Adv Sci (Weinh), 2023, 10(23): e2205563.

[16] LI Z, LIU Y, HUANG X, et al. Nucleatum enhances oral squamous cell carcinoma proliferation via E-cadherin/β-Catenin pathway[J]. BMC Oral Health, 2024, 24(1): 518.

[17] YE C, LIU X, LIU Z, et al. Fusobacterium nucleatum in tumors: From tumorigenesis to tumor metastasis and tumor resistance[J]. Cancer Biol Ther, 2024, 25(1): 2306676.

[18] GEDEFIE A, DEMSIS W, ASHAGRIE M, et al. Acinetobacter baumannii biofilm formation and its role in disease pathogenesis: A review[J]. Infect Drug Resist, 2021, 14: 3711-3719.

[19] 陈肖, 王立坤, 刘卫东, 等 . 鲍曼不动杆菌的致病因子和耐药机制[J]. 国际流行病学传染病学杂志, 2021, 48(2): 162-165.

[20] MORRIS F C, DEXTER C, KOSTOULIAS X, et al. The mechanisms of disease caused by Acinetobacter baumannii [J]. Front Microbiol, 2019, 10: 1601.

[21] VESEL N, ISELI C, GUEX N, et al. DNA modifications impact natural transformation of Acinetobacter baumannii [J]. Nucleic Acids Res, 2023, 51(11): 5661-5677.

[22] TIKU V, KOFOED E M, YAN D, et al. Outer membrane vesicles containing OmpA induce mitochondrial fragmentation to promote pathogenesis of Acinetobacter baumannii [J]. Sci Rep, 2021, 11(1): 618.

[23] WENG Z, YANG N, SHI S, et al. Outer membrane vesicles from Acinetobacter baumannii: Biogenesis, functions, and vaccine application[J]. Vaccines (Basel), 2023, 12(1): 49.

[24] RAMIREZ M S, BONOMO R A, TOLMASKY M E. Carbapenemases: Transforming Acinetobacter baumannii into a yet more dangerous menace[J]. Biomolecules, 2020, 10(5): 720.

[25] MIAO Y, TANG H, ZHAI Q, et al. Gut microbiota dysbiosis in the development and progression of gastric cancer[J]. J Oncol, 2022, 2022: 9971619.

[26] MOHR A E, CRAWFORD M, JASBI P, et al. Lipopolysaccharide and the gut microbiota: Considering structural variation[J]. FEBS Lett, 2022, 596(7): 849-875.

[27] CHEN S, LEI Q, ZOU X, et al. The role and mechanisms of gram-negative bacterial outer membrane vesicles in inflammatory diseases[J]. Front Immunol, 2023, 14: 1157813.

[28] SHADAN A, PATHAK A, MA Y, et al. Deciphering the virulence factors, regulation, and immune response to Acinetobacter baumannii infection[J]. Front Cell Infect Microbiol, 2023, 13: 1053968.

[29] CHEN F, GUO S, LI Y, et al. Fusobacterium nucleatum-driven CX3CR1⁺ PD-L1⁺ phagocytes route to tumor tissues and reshape tumor microenvironment[J]. Gut Microbes, 2025, 17(1): 2442037.

[30] YASUDA T, WANG Y A. Gastric cancer immunosuppressive microenvironment heterogeneity: Implications for therapy development[J]. Trends Cancer, 2024, 10(7): 627-642.

[31] HOU W, ZHAO Y, ZHU H. Predictive biomarkers for immunotherapy in gastric cancer: Current status and emerging prospects[J]. Int J Mol Sci, 2023, 24(20): 15321.

[32] ENGSTRAND L, GRAHAM D Y. Microbiome and gastric cancer[J]. Dig Dis Sci, 2020, 65(3): 865-873.

[33] ZHENG D, LIWINSKI T, ELINAV E. Interaction between microbiota and immunity in health and disease[J]. Cell Res, 2020, 30(6): 492-506.

[34] DOUGHERTY M W, JOBIN C. Intestinal bacteria and colorectal cancer: Etiology and treatment[J]. Gut Microbes, 2023, 15(1): 2185028.

[35] WANG G, HUANG Y, ZHOU L, et al. Immunotherapy and targeted therapy as first-line treatment for advanced gastric cancer[J]. Crit Rev Oncol Hematol, 2024, 198: 104197.

[36] WANG Y, HAN W, WANG N, et al. The role of microbiota in the development and treatment of gastric cancer[J]. Front Oncol, 2023, 13: 1224669.

[37] ALMEIDA R S, WISNIESKI F, TAKAO REAL KARIA B, et al. CRISPR/Cas9 genome-editing technology and potential clinical application in gastric cancer[J]. Genes (Basel), 2022, 13(11): 2029.

[38] LIU Q, WANG L, HE D, et al. Application value of antimicrobial peptides in gastrointestinal tumors[J]. Int J Mol Sci, 2023, 24(23): 16718.

[39] ZHOU C B, ZHOU Y L, FANG J Y. Gut microbiota in cancer immune response and immunotherapy[J]. Trends Cancer, 2021, 7(7): 647-660.

[40] 罗晓霞, 覃思华, 王晖迪, 等 . 细菌外囊泡在疾病发生发展中的作用机制及应用前景[J]. 协和医学杂志, 2023, 14(5): 915-924.

[41] HUANG W, MENG L, CHEN Y, et al. Bacterial outer membrane vesicles as potential biological nanomaterials for antibacterial therapy[J]. Acta Biomater, 2022, 140: 102-115.

[42] LI N, YU Y, CHEN Q, et al. A gene delivery system with autophagy blockade for enhanced anti-angiogenic therapy against Fusobacterium nucleatum-associated colorectal cancer[J]. Acta Biomater, 2024, 183: 278-291.

[43] MONDAL S, ADHIKARI N, BANERJEE S, et al. Matrix metalloproteinase-9 (MMP-9) and its inhibitors in cancer: A minireview[J]. Eur J Med Chem, 2020, 194: 112260.

[44] GETHINGS-BEHNCKE C, COLEMAN H G, JORDAO H W T, et al. Fusobacterium nucleatum in the colorectum and its association with cancer risk and survival: A systematic review and meta-analysis[J]. Cancer Epidemiol, 2020, 29(3): 539-548.

[45] GUAN W L, HE Y, XU R H. Gastric cancer treatment: Recent progress and future perspectives[J]. J Hematol Oncol, 2023, 16(1): 57.

基金资助

兰州市科技计划项目(2023-2-6)

兰州大学“萃英科技创新”计划项目(CY2023-BJ-06)